

Format for ANSWERING REVIEWERS



December 10, 2014

Dear Editor,

Please find enclosed the edited manuscript in Word format

Title: Tumor lysis syndrome: a clinical review.

Authors: Aibek E. Mirrakhimov, Prakruthi Voore, Maliha Khan, Alaa M. Ali.

Name of Journal: *World Journal of Critical Care Medicine*

ESPS Manuscript NO: 14536

The manuscript has been improved according to the suggestions of reviewers:

Response to reviewer #1:

1. All the changes suggested by the reviewer were implanted. Changes made are highlighted in yellow color.

Response to reviewer #2:

1. The suggestion provided by the reviewer regarding the use of phrases such as "in our practice", "we typically" and "we do not recommend". These phrases were changed to more neutral and are highlighted in yellow.

2. We agree with reviewer regarding very limited data on the use of febuxostat in patients with tumor lysis syndrome. We have rewritten this paragraph.

3. The section on allopurinol is rewritten. The route of administration was added, the mechanism of action and the figure was added. The section of allopurinol toxicity was rewritten as advised.

4. The language was edited.

5. Suggestion regarding the addition of micromole/l was added.

6. The section on rasburicase side effects and contraindication was added.

7. Table 1 was modified as suggested (phosphorus).

8. Abbreviations in table 2 were defined.

9. Table 2 was modified (upper limit of normal was provided).

III. References and typesetting were corrected whenever appropriate

Thank you again for kind editorial stance to our manuscript in the *World Journal of Critical Care Medicine*.

Sincerely yours,

Aibek E. Mirrakhimov, MD
Department of Internal Medicine
Saint Joseph Hospital
Chicago, Illinois
Tel: 773-665-3015
Fax: 773-665-3384
Email: amirrakhimov1@gmail.com